Latest News and Press Releases
Want to stay updated on the latest news?
-
New grants add to the strong core patents previously granted in the US, Europe and other countries SAN DIEGO, CA, March 16, 2020 (GLOBE NEWSWIRE) -- Emerald Health Pharmaceuticals Inc....
-
First-in-class product candidate in Phase 2 clinical development now has Fast Track and Orphan designations SAN DIEGO, CA, March 03, 2020 (GLOBE NEWSWIRE) -- Emerald Health Pharmaceuticals Inc....
-
Emerald’s lead product candidate, EHP-101, shows potential disease-modifying capabilities in multiple sclerosis, further supporting advancement into Phase II clinical development SAN DIEGO, CA, Feb. ...
-
SAN DIEGO, CA, Feb. 19, 2020 (GLOBE NEWSWIRE) -- Emerald Health Pharmaceuticals Inc. (EHP), a clinical-stage pharmaceutical company developing medicines based on cannabinoid science, has been...
-
Follows the success of obtaining Orphan Drug Designation for Huntington’s Disease in the US SAN DIEGO, CA, Jan. 29, 2020 (GLOBE NEWSWIRE) -- Emerald Health Pharmaceuticals Inc. (EHP), a...
-
SAN DIEGO, CA, Jan. 13, 2020 (GLOBE NEWSWIRE) -- Emerald Health Pharmaceuticals Inc. (EHP), a clinical-stage biotechnology company developing medicines based on cannabinoid science, announced today...
-
SAN DIEGO, CA, Sept. 03, 2019 (GLOBE NEWSWIRE) -- Emerald Health Pharmaceuticals Inc. (EHP), a clinical-stage company developing medicines based on cannabinoid science, announced today that Jim...
-
Phase I study of CBD-derived drug candidate demonstrates safety and tolerability in over 100 subjects Phase II studies planned to start before year-end SAN DIEGO, CA, Aug. 26, 2019 ...
-
Preclinical data show remyelination with the clinical-stage drug product candidate, EHP-101 SAN DIEGO, CA, July 02, 2019 (GLOBE NEWSWIRE) -- Emerald Health Pharmaceuticals Inc. (EHP), a...
-
EHP-102 and other novel cannabigerol derivatives from Emerald Health Pharmaceuticals demonstrate therapeutic potential in validated animal models SAN DIEGO, CA, July 02, 2019 (GLOBE NEWSWIRE)...